Faslodex-Arimidex Improves Survival in Post-menopausal Women with Advanced BC, Trial Shows

Faslodex-Arimidex Improves Survival in Post-menopausal Women with Advanced BC, Trial Shows
First-line treatment with Arimidex (anastrozole) plus Faslodex (fulvestrant) prolongs the lives of post-menopausal women with hormone receptor (HR)-positive advanced breast cancer, particularly those who have never taken tamoxifen, results of a clinical trial show. The study, “Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer,” was published in the New England Journal of Medicine. Faslodex, developed by AstraZeneca, is approved for HR-positive advanced breast cancer in women who have been through menopause, including those who have not received prior hormone therapy, also known as endocrine therapy (e.g. the anti-estrogen medication tamoxifen), and those whose cancer got worse after taking a hormonal treatment. Is is also indicated as an add-on treatment for women with HR-positive breast tumors whose cancer has spread to other parts of the body and has worsened following hormone therapy. Faslodex is also an anti-estrogen drug. It works by selectively blocking estrogen receptors, halting that hormone’s effect on tumor cells. As a consequence, it slows or stops the growth of HR-positive breast cancers, which depend on estrogen to proliferate. Arimidex, also by AstraZeneca, is also a hormonal therapy, but prevents the effects of estrogen through a different mechanism. It is an aromatase inhibitor, blocking the production of estrogen by inhibiting aromatase, an enzyme necessary for this process. The medicine is used primarily in post-menopausal women because before menopause the ovaries produce too much aromatase for the inhibitor to block them effectively. But despite treatment with Arimidex, postmenopausal women with advanced breast cancer have a poor prognosis. In some cases, tumors become resistant to treatment be
Subscribe or to access all post and page content.